P

Phio Pharmaceuticals Corp

D
PHIO
USD
0
(0%)
Market Closed
1,985.00
Volume
-16.38
EPS
-
Div Yield
-0.201488
P/E
2,797,343.25
Market Cap
Today
-0.3067%
1 Week
8.333%
1 Month
8.696%
6 Months
-57.046%
12 Months
-70.641%
Year To Date
-53.078%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
MRNA
MRNA
-1.49
(-2.8776%)
USD
N
NVAX
0.23
(2.5713%)
USD
I
INO
-0.13
(-2.2968%)
USD
B
BNTX
0.99
(0.9269%)
USD
V
VXRT
0.0125
(1.7576%)
USD
A
ABUS
-0.195
(-4.9618%)
USD
A
ARCT
0.45
(2.4563%)
USD
V
VIR
-0.385
(-3.7894%)
USD
A
ALT
0.155
(2.1218%)
USD

Title:
Phio Pharmaceuticals Corp

Sector:
Healthcare
Industry:
Biotechnology
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Do you need help or have a question?
Contact Us